iBio, Inc. IBIO
iBio, Inc. (Nasdaq: IBIO) is a cardio-renal-metabolic drug developer. Its lead program, IBIO-600, is in Phase 1 for Obesity (long-acting myostatin antibody). Its next catalyst on record is IBIO-610: Commence first-in-human clinical trial (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: IBIO-610 — Commence first-in-human clinical trial (H1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IBIO-600 | Obesity / cardiometabolic (myostatin antibody) | antibody | Phase 1 |
| IBIO-610 | Obesity (long-acting Activin E antibody) | antibody | Pre-clinical |
| IBIO-800 | PH-HFpEF (myostatin x Activin A bispecific antibody) | antibody | Pre-clinical |
Recent results and decisions
- Apr 8, 2026accepted Australian TGA CTN acknowledgement and HREC approval received for first-in-human Phase 1 of IBIO-600; first participant dosing expected 2Q 2026 (ex-US regulator).
iBio expects to dose the first participant in the second quarter of 2026.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.